Search hospitals > Connecticut > West Haven

CERC (VISN1, West Haven, CT)

Claim this profile
West Haven, Connecticut 06516
Conducts research for Major Depressive Disorder
Conducts research for Driving While Intoxicated
Conducts research for Hangover
Conducts research for Active Ethanol and Active Iomazenil
Conducts research for Driving Under the Influence (DUI)
5 reported clinical trials
4 medical researchers
Photo of CERC (VISN1, West Haven, CT) in West HavenPhoto of CERC (VISN1, West Haven, CT) in West HavenPhoto of CERC (VISN1, West Haven, CT) in West Haven

Summary

CERC (VISN1, West Haven, CT) is a medical facility located in West Haven, Connecticut. This center is recognized for care of Major Depressive Disorder, Driving While Intoxicated, Hangover, Active Ethanol and Active Iomazenil, Driving Under the Influence (DUI) and other specialties. CERC (VISN1, West Haven, CT) is involved with conducting 5 clinical trials across 12 conditions. There are 4 research doctors associated with this hospital, such as Mohini Ranganathan, MD, Gihyun Yoon, MD, Toral Surti, MD, and Capurso Noah, MD.

Top PIs

Mohini Ranganathan, MDConnecticut Mental Health Center4 years of reported clinical research
Studies Substance Abuse
Studies Healthy Subjects
8 reported clinical trials
11 drugs studied
Gihyun Yoon, MDCERC (VISN1, West Haven, CT)1 year of reported clinical research
Studies Post-Traumatic Stress Disorder
Studies Alcoholism
4 reported clinical trials
9 drugs studied
Toral Surti, MDCERC (VISN1, West Haven, CT)4 years of reported clinical research
Studies Insomnia
1 reported clinical trial
4 drugs studied
Capurso Noah, MDCERC (VISN1, West Haven, CT)5 years of reported clinical research
Studies Opiate Dependence
Studies Opioid Use Disorder
1 reported clinical trial
2 drugs studied

Clinical Trials running at CERC (VISN1, West Haven, CT)

Opiate Dependence
Opioid Use Disorder
Image of trial facility.

Buprenorphine Forms

for Opioid Use Disorder

VA-BRAVE will determine whether a 28-day long-acting injectable sub-cutaneous formulation of buprenorphine at a target dose of 300mg is superior in retaining Veterans in opioid treatment and in sustaining opioid abstinence compared to the daily sublingual (under the tongue) buprenorphine formulation at a target dose of 4-32 mg (standard of care). This is an open-label, randomized, controlled trial including 952 Veterans with opioid use disorder (OUD) recruited over 7 years and followed actively for 52 weeks. There are a number of secondary objectives that will be studied as well and include: comorbid substance use, both non-fatal and fatal opioid overdose, HIV and Hepatitis B (HBV) and C (HCV) testing results and risk behaviors, incarceration, quality of life, psychiatric symptoms of depression and posttraumatic stress disorder, housing status, dental health and utilization, and cost-effectiveness.
Recruiting3 awards Phase 43 criteria

Similar Hospitals nearby

Select from list below to view details

Frequently asked questions

What kind of research happens at CERC (VISN1, West Haven, CT)?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security